← All trials
NCT01627132
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 1, 2012
- Primary completion
- Feb 1, 2017
- Completion date
- Jan 1, 2019
- First posted
- —
- Last posted
- —
- Enrollment
- 50
- Arms / groups
- 1 / —
- Source
- AACT · pre-existing
Sponsors
- Shimousa Hematology Study GroupLead sponsor
- Epidemiological and Clinical Research Information NetworkCollaborator
- Nippon Medical SchoolOverall official - principal investigator
- Shimousa Hematology Study GroupReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.